arrow
C

Carsten Kobe

faculty of medicine and university hospital cologne
H指数:44
被引数:7,229

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Validation of the newly introduced Deauville Score 5a in patients treated for advanced-stage classic Hodgkin Lymphoma

对接受治疗的前期经典霍奇金淋巴瘤患者中新引入的Deauville Score 5a评分的验证

2026-07-020
OA
Gonadal Function and Fertility after Hodgkin Lymphoma Treatment with Nivolumab-AVD in the Phase 2 GHSG NIVAHL Trial

Gonadal Function and Fertility after Hodgkin Lymphoma Treatment with Nivolumab-AVD in the Phase 2 GHSG NIVAHL Trial

Blood
IF23.1
2026-04-070
PRE
Brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone for advanced-stage Hodgkin lymphoma in older patients

Brentuximab vedotin、环磷酰胺、多柔比星和泼尼松用于老年晚期霍奇金淋巴瘤患者

2025-08-180
OA
PET imaging utilization and trends in Germany: a comprehensive survey

德国正电子发射断层扫描(PET)成像的应用与趋势:一项综合调查

2025-05-030
OA
Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) Trials (MAR, 10.1038/s41375-025-02567-w, 2025)

复发霍奇金淋巴瘤治疗后无进展生存期和总生存期的相关性:德国霍奇金研究小组(GHSG)随机试验的个体患者数据分析(MAR, 10.1038/s41375-025-02567-w, 2025)

LEUKEMIA
IF13.4
2025-03-300
OA
Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) Trials: LYMPHOMA

复发霍奇金淋巴瘤治疗后无进展生存期与总生存期的相关性:德国霍奇金研究组(GHSG)随机试验的个体患者数据分析:LYMPHOMA

LEUKEMIA
IF13.4
2025-03-241
OA
Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapy

你知道你的psma-tracer吗?不同PSMA配体的生物分布的变异性及其对PSMA靶向治疗前定义PSMA阳性的潜在影响

2025-01-100
OAAI
Correlation between progression-free and overall survival in patients with Hodgkin lymphoma: a comprehensive analysis of individual patient data from randomized German Hodgkin Study Group (GHSG) trials

霍奇金淋巴瘤患者无进展生存期与总生存期的相关性:一项基于德国霍奇金研究小组(GHSG)随机试验个体患者数据的综合分析

2024-12-017
OAAI
Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma-An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group
2024-12-011
OAAI
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

评估PET引导的BrECADD与eBEACOPP在晚期经典霍奇金淋巴瘤 (HD21) 中的疗效和耐受性: 一项随机,多中心,平行,开放标签的3期试验

LANCET
IF88.5
2024-07-019
OAAI